Ketamine was presented monetarily in 1970 with the producer’s portrayal being “quickly acting, nonbarbiturate general sedative” along with an idea particularly can remain helpful for small techniques. As a result of its old exceptional pharmaceutic properties and recently discovered gainful remedial resources, ketamine has endure the solid breezes of phase and it right now has a broad assortment of remedial utilizations. It’s recently discovered neurotoxic, calming and anticancer impacts and the conclusion of the helpfulness of small portion ketamine control have assisted with enlarging the remedial application profile of ketamine. Ketamine, a extensive NMDA receptor foe, is utilized generally in medication as a sedative specialist. The current article endeavours to audit the current valuable uses of ketamine in sedation, torment and basic consideration.
REFERENCES
1.
Abdollahpour,
E.
Saffarieh
, and B. H.
Zoroufchi
, “A review on the recent application of ketamine in management of anesthesia, pain, and health care
,” J. Fam. Med. Prim. Care
, vol. 9
, no. 3
, p. 1317
, 2020
, doi: .2.
K. A.
Sheehy
, C.
Lippold
, A. L.
Rice
, R.
Nobrega
, J. C.
Finkel
, and Z. M. N.
Quezado
, “Subanesthetic ketamine for pain management in hospitalized children, adolescents, and young adults: A single-center cohort study
,” J. Pain Res.
, vol. 10
, pp. 787
–795
, Apr. 2017
, doi: .3.
M.
Kurdi
, K.
Theerth
, and R.
Deva
, “Ketamine: Current applications in anesthesia, pain, and critical care
,” Anesth. Essays Res.
, vol. 8
, no. 3
, p. 283
, 2014
, doi: .4.
S. P.
Cohen
et al, “Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists
,” Regional Anesthesia and Pain Medicine
, vol. 43
, no. 5
. Lippincott Williams and Wilkins, pp. 521
–546
, Jul. 01, 2018
, doi: .5.
B.
Assouline
, M. R.
Tramèr
, L.
Kreienbühl
, and N.
Elia
, “Benefit and harm of adding ketamine to an opioid in a patient-controlled analgesia device for the control of postoperative pain: Systematic review and meta-analyses of randomized controlled trials with trial sequential analyses
,” Pain
, vol. 157
, no. 12
. Lippincott Williams and Wilkins, pp. 2854
–2864
, Aug. 10, 2016
, doi: .6.
A.
Gales
and S.
Maxwell
, “Ketamine: Recent Evidence and Current Uses
,” 2018. Accessed: Apr. 09, 2021. [Online]. Available: www.wfsahq.org/resources/anaesthesia-tutorial-of-the-week.7.
V.
Martinez
, B.
Derivaux
, and H.
Beloeil
, “Ketamine for pain management in France, an observational survey
,” Anaesth. Crit. Care Pain Med.
, vol. 34
, no. 6
, pp. 357
–361
, Dec. 2015
, doi: .8.
A.
Dahan
, K.
Jonkman
, T.
van de Donk
, L.
Aarts
, M.
Niesters
, and M.
van Velzen
, “Ketamine for pain
,” F1000Research
, vol. 6
. Faculty of 1000 Ltd, 2017
, doi: .9.
B.
Antkowiak
, “Different actions of general anesthetics on the firing patterns of neocortical neurons mediated by the GABA(A) receptor
,” Anesthesiology
, vol. 91
, no. 2
, pp. 500
–511
, Aug. 1999
, doi: .10.
L. M.
Monteggia
and C.
Zarate
, “Antidepressant actions of ketamine: From molecular mechanisms to clinical practice
,” Current Opinion in Neurobiology
, vol. 30
. Elsevier Ltd
, pp. 139
–143
, Feb. 01, 2015
, doi: .11.
R. C.
Dart
et al, “Trends in Opioid Analgesic Abuse and Mortality in the United States
,” N. Engl. J. Med.
, vol. 372
, no. 3
, pp. 241
–248
, Jan. 2015
, doi: .12.
V. H.
Maddox
, E. F.
Godefboi
, and R. F.
Parcell
, “The Synthesis of Phencyclidine and Other 1-Arylcyclohexylamines
,” J. Med. Chem.
, vol. 8
, no. 2
, pp. 230
–235
, Mar. 1965
, doi: .13.
Acmd
, “ACMD Advisory Council on the Misuse of Drugs Ketamine: a review of use and harm
,” 2013
.14.
S.
Goyal
and A.
Agrawal
, “Ketamine in status asthmaticus: A review
,” Indian Journal of Critical Care Medicine
, vol. 17
, no. 3
. Indian Society of Critical Care Medicine
, pp. 154
–161
, May 2013, doi: .15.
M. W.
Tyler
, H. B.
Yourish
, D. F.
Ionescu
, and S. J.
Haggarty
, “Classics in Chemical Neuroscience: Ketamine
,” ACS Chem. Neurosci.
, vol. 8
, no. 6
, pp. 1122
–1134
, Apr. 2017
, doi: .16.
S.
Reardon
, “Rave drug tested against depression
,” Nature
, vol. 517
, no. 7533
. Nature, pp. 130
–131
, Jan. 08, 2015
, doi: .17.
I. S.
Grant
, W. S.
Nimmo
, and J. A.
Clements
, “Pharmacokinetics and analgesic effects of I.M. and oral ketamine
,” Br. J. Anaesth.
, vol. 53
, no. 8
, pp. 805
–810
, 1981
, doi: .18.
B.
Ebert
, S.
Mikkelsen
, C.
Thorkildsen
, and F. M.
Borgbjerg
, “Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord
,” Eur. J. Pharmacol.
, vol. 333
, no. 1
, pp. 99
–104
, Aug. 1997
, doi: .19.
V. P. Borkar
Patil
and J. J.
Upadhye
, “Ketamine and propofol: safe for short procedures
,” Int. J. Res. Med. Sci.
, vol. 7
, no. 7
, p. 2744
, Jun. 2019
, doi: .20.
M.
Ezici
, A.
Bestas
, and O. L.
Erhan
, “As an analgesic ketamine versus fentanyl for total intravenous anesthesia
,” Saudi Journal of Anaesthesia
, vol. 7
, no. 1
. Wolters Kluwer -- Medknow Publications, pp. 107
–108
, Jan. 2013
, doi: .21.
E.
Visser
and S. A.
Schug
, “The role of ketamine in pain management
,” Biomed. Pharmacother.
, vol. 60
, no. 7
, pp. 341
–348
, Aug. 2006
, doi: .22.
V.
Pešić
, J.
Petrović
, and M. M
Jukić
, “Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant
,” Drug Dev. Res.
, vol. 77
, no. 7
, pp. 414
–422
, Nov. 2016
, doi: .23.
S. J.
Mathew
et al, “Ketamine for treatment-resistant unipolar depression: Current evidence
,” CNS Drugs
, vol. 26
, no. 3
, pp. 189
–204
, 2012
, doi: .24.
G.
Mion
and T.
Villevieille
, “Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings
),” CNS Neuroscience and Therapeutics
, vol. 19
, no. 6
. CNS Neurosci Ther
, pp. 370
–380
, Jun. 2013
, doi: .25.
L. A.
Jelen
, A. H.
Young
, and J. M.
Stone
, “Ketamine: A tale of two enantiomers
,” Journal of Psychopharmacology
, vol. 35
, no. 2
. SAGE Publications Ltd, pp. 109
–123
, Feb. 01, 2021
, doi: .26.
I.
Barenboim
and B.
Lafer
, “Maintenance use of ketamine for treatmentresistant depression: An open-label pilot study
,” Revista Brasileira de Psiquiatria
, vol. 40
, no. 1
. Associacao Brasileira de Psiquiatria, p. 110
, Jan. 01, 2018
, doi: .27.
P. R.
Shiroma
et al, “Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression
,” J. Affect. Disord.
, vol. 155
, no. 1
, pp. 123
–129
, Feb. 2014
, doi: .28.
M. S.
Lener
, B.
Kadriu
, and C. A.
Zarate
, “Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
,” Drugs
, vol. 77
, no. 4
. Springer International Publishing, pp. 381
–401
, Mar. 01, 2017
, doi: .29.
W. C.
Duncan
and C. A.
Zarate
, “Ketamine, sleep, and depression: Current status and new questions
,” Curr. Psychiatry Rep.
, vol. 15
, no. 9
, pp. 1
–7
, Sep. 2013
, doi: .30.
W. C.
Duncan
et al, “Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
,” Int. J. Neuropsychopharmacol.
, vol. 16
, no. 2
, pp. 301
–311
, Mar. 2013
, doi: .31.
W. C.
Duncan
, E. D.
Ballard
, and C. A.
Zarate
, “Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood
,” in Handbook of Experimental Pharmacology
, vol. 253
, Springer New York LLC
, 2019
, pp. 337
–358
.32.
A.
Pribish
, N.
Wood
, and A.
Kalava
, “A Review of Nonanesthetic Uses of Ketamine
,” Anesthesiology Research and Practice
, vol. 2020
. Hindawi Limited
, 2020
, doi: .33.
W. C.
Duncan
, J.
Selter
, N.
Brutsche
, S.
Sarasso
, and C. A.
Zarate
, “Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder
,” J. Affect. Disord.
, vol. 145
, no. 1
, pp. 115
–119
, Feb. 2013
, doi: .34.
E. D.
Ballard
et al, “Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety
,” J. Psychiatr. Res.
, vol. 58
, pp. 161
–166
, Nov. 2014
, doi: .35.
Y.
Lee
et al, “A new perspective on the anti-suicide effects with ketamine treatment a procognitive effect
,” J. Clin. Psychopharmacol.
, vol. 36
, no. 1
, pp. 50
–56
, 2016
, doi: .36.
C.
Wu
et al, “Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus
,” Neurobiol. Learn. Mem.
, vol. 167
, Jan. 2020
, doi: .37.
C. G.
Abdallah
, R.
Salas
, A.
Jackowski
, P.
Baldwin
, J. R.
Sato
, and S. J.
Mathew
, “Hippocampal volume and the rapid antidepressant effect of ketamine
,” J. Psychopharmacol.
, vol. 29
, no. 5
, pp. 591
–595
, May 2015
, doi: .38.
C. J. A.
Morgan
and H. V.
Curran
, “Acute and chronic effects of ketamine upon human memory: A review
,” Psychopharmacology
, vol. 188
, no. 4
. Psychopharmacology (Berl), pp. 408
–424
, Nov. 2006
, doi: .39.
Y.
Zhou
et al, “Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression
,” J. Psychopharmacol.
, vol. 32
, no. 10
, pp. 1118
–1126
, Oct. 2018
, doi: .40.
W.
Liu
et al, “Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression
,” J. Affect. Disord.
, vol. 259
, pp. 1
–6
, Dec. 2019
, doi: .41.
M. H.
Chen
et al, “Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion
,” J. Affect. Disord.
, vol. 241
, pp. 1
–7
, Dec. 2018
, doi: .42.
G.
Salvadore
et al, “Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine
,” Biol. Psychiatry
, vol. 65
, no. 4
, pp. 289
–295
, Feb. 2009
, doi: .43.
C. G.
Abdallah
et al, “Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients
,” Chronic Stress
, vol. 2
, 2018
, doi: .44.
C. G.
Abdallah
et al, “The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder
,” Neuropsychopharmacology
, vol. 42
, no. 8
, pp. 1739
–1746
, Jul. 2017
, doi: .
This content is only available via PDF.
©2023 Authors. Published by AIP Publishing.
2023
Author(s)
You do not currently have access to this content.
